IFN-β mediates the anti-osteoclastic effect of bisphosphonates and dexamethasone

• Egile Nagusiak: Prajakta Kalkar (Egilea), Gal Cohen (Egilea), Tal Tamari (Egilea), Sagie Schif-Zuck (Egilea), Hadar Zigdon-Giladi (Egilea), Amiram Ariel (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2022-10-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Zoledronic acid (Zol) is a potent bisphosphonate that inhibits the differentiation of monocytes into osteoclasts. It is often used in combination with dexamethasone (Dex), a glucocorticoid that promotes the resolution of inflammation, to treat malignant diseases, such as multiple myeloma. This treat...